Significance of Surgery in the Treatment of Colorectal Cancer Ovarian Metastases: A Retrospective Case Matching Study

This article was published in the following Dove Press journal:
Cancer Management and Research

Yuqiu Xu*
Qingyang Feng*
Yijiao Chen*
Yihao Mao*
Zhiyuan Zhang
Yang Lv*
Peng Zheng
Shanchao Yu
Guodong He
Jianmin Xu

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Purpose: Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Ovarian metastases (OM), which are low in frequency, are reported to occur in 3–14% of women with CRC and have a poor prognosis. Studies have shown that surgical treatment may benefit patients with ovarian metastases arising from CRC. However, the precise benefit of surgery is uncertain. This study was implemented to identify treatment outcomes associated with ovarian metastases from CRC, as well as to clarify the importance of primary and metastatic lesion resection.

Patients and Methods: Between January 2008 and December 2018, the medical records of 93 patients diagnosed with CRC ovarian metastases (CRC-OM) at Zhongshan Hospital, Fudan University, Shanghai, were retrospectively analyzed. Clinicopathological characteristics as well as prognostic conditions were evaluated. Nineteen patients with only synchronous OM and 38 patients without metastases were matched to compare surgical outcomes.

Results: The median overall survival (OS) of the total 93 CRC-OM patients was 26 months. The median OS times of patients with ovary-only metastases (n=37) and those with other metastases (n=56) were 49 months and 20 months, respectively. Patients with only ovarian metastases had a longer OS time (p<0.001) than patients with other metastases. Patients with ovarian metastases resected (n=76) (p<0.001) had a longer OS time than those unresected (n=17). Synchronous (n=54) and metachronous (n=39) metastases indicated no significant survival difference. Patients with only ovarian metastases could achieve similar OS times to those of patients without metastases after primary and metastasis surgery.

Conclusion: Surgical treatment is very important for CRC-OM patients. Primary and metastatic lesion resection can help achieve longer survival times.

Keywords: colorectal cancer, metastases, ovary, prognosis

Introduction
Colorectal cancer (CRC) is one of the most common malignancies. The incidence and mortality rates of CRC in China have shown an increasing trend in the past 10 years.\textsuperscript{1,2} CRC has become one of the most common primary sites of ovarian metastases.\textsuperscript{3} Ovarian metastases from CRC, although relatively rare, are a major cause of death among female patients. Grahnner et al\textsuperscript{4} reported that 3–8% of patients with CRC had visible ovarian metastases, while autopsy showed that 14% of patients had ovarian metastases.

The number of ovarian metastasis cases has increased with the increasing incidence of CRC. Thus, improving the prognosis of patients with ovarian metastases is...
becoming increasingly urgent. Since the prognosis of ovarian metastases is very poor and since ovarian metastases are not sensitive to chemotherapy,\textsuperscript{5,6} the current study has focused on exploring whether surgical resection of metastases can be an effective treatment for CRC-OM.

Many scholars have been involved in the discussion of the value of surgery; however, the factors that affect the prognosis of patients undergoing surgery are still controversial, and the advantages of surgery have not been well defined or proven.\textsuperscript{7} Moreover, there is no report concerning whether the survival of patients with ovarian metastases can reach the survival level of patients without ovarian metastases.

In this paper, we retrospectively studied the prognosis of patients with CRC-OM and explored the influence of surgery on CRC-OM. We aimed to further clarify the importance of primary and metastatic resection in the treatment of ovarian metastases arising from CRC.

**Methods**

**Patients**

A total of 93 patients were diagnosed with CRC-OM based on radiological and pathological findings between January 2008 and December 2018 at Zhongshan Hospital, Fudan University, Shanghai. The details of the patients diagnosed by radiography were discussed by members of a multidisciplinary team (MDT), including radiologists, surgeons and gynecologists, to determine their diagnosis of CRC-OM. Synchronous metastases were defined as ovarian metastases detected at the same time as CRC. Metachronous metastases were defined as ovarian metastases detected after the time of CRC. Follow-up information was collected until December 2019. Disease-free survival (DFS) and OS were evaluated from the initial diagnosis of CRC-OM. Clinicopathological characteristics as well as prognostic conditions were retrospectively analyzed. Our study was performed in accordance with the standards of the Ethical Committee of Fudan University Zhongshan Hospital.

**Matching**

To compare surgical outcomes between CRC patients with and without ovarian metastases, 19 patients with only synchronous ovarian metastases were used for 1:2 matching. From January 2008 to December 2018, 4635 female patients underwent CRC surgical excision at Zhongshan Hospital. After 763 synchronous metastatic patients were excluded, 3872 patients were available for matching. The following factors were taken into consideration for 1:2 matching: age, preoperative radiotherapy or chemotherapy, primary tumor site, primary tumor size, T stage, N stage, primary tumor gross type, primary tumor histology and primary tumor differentiation. In this way, 38 patients were included in the 1:2 matched group (Figure 1).

**Statistical Analysis**

Survival was analyzed with the Kaplan–Meier method and was compared using the Log rank test. Variables found to

---

**Figure 1** Flow chart of the matching of synchronous ovary-only metastasis patients and CRC patients with no metastases.
be significant (P<0.05) by univariate analysis were further analyzed using a multivariate Cox proportional hazards regression model. Significant factors by Cox’s analysis are expressed as hazard ratios (HR values) with 95% confidence intervals (CIs). When the differences in clinicopathologic features between patients with synchronous and metachronous metastases and between patients with synchronous ovarian metastases and without metastases patients were analyzed, continuous variables were compared using Student’s t-test or the Mann–Whitney U-test. Categorical variables were compared with Pearson’s chi-square test. SPSS, version 25.0 (SPSS, Chicago, IL, USA), was used for analysis. GraphPad Prism, version 7.00 (GraphPad, San Diego, California, USA), was employed to draw the curves. All statistical tests were two-sided, and p values <0.05 were considered statistically significant.

Results

Patient Characteristics

Ninety-three patients with CRC-OM were enrolled in this study. Synchronous metastases were detected in 54 cases and metachronous metastases in 39 cases. Eleven patients did not receive surgery for either primary tumor lesions or ovarian metastases, 6 patients did not receive resection for ovarian metastases but did for primary tumor sites, and 76 patients underwent surgical resection of primary CRC and ovarian metastases. Among patients who underwent primary and ovarian metastases surgery, 42 were synchronous metastasis patients and 34 were metachronous metastasis patients. The median follow-up time was 17 months (range: 0–95). The mean age at diagnosis of CRC was 50.07 years (range: 26–78, SD: 12.82). The mean age at diagnosis of ovarian metastases was 50.66 years (range: 26–78, SD: 12.90). A total of 59.1% (n=55) of patients were premenopausal. Nearly half of the primary tumors (n=43) originated from the left colon. The percentages of patients with synchronous metastases and metachronous metastases were 58.1% (n=54) and 41.9% (n=39), respectively. The median interval of metachronous metastases was 12 months (range: 3–43). More than half of the patients (n=56) had both ovarian metastases and other metastases. Eleven patients received preoperative chemotherapy. Eighty-six (92.5%) patients received different adjuvant chemotherapy regimens after the operation (Table 1). As analyzed by the Kaplan–Meier method, the median OS of CRC-OM patients was 26 months (Figure 2A), while the median OS times of patients with ovari-only metastases and those with ovarian metastases combined with other metastases patients were 49 months and 20 months, respectively (Figure 2B and C).

Factors Affecting the Survival of Patients with CRC-OM

Univariate analysis showed that patients with only ovarian metastases had a longer OS time (HR (95% CI), 5.331

Table 1 Baseline Characteristics of All Patients with CRC-OM

| Variables | n | Mean (±SD) |
|-----------|---|------------|
| Age at diagnosis of colorectal cancer, years (±SD) | | |
| ≤50 | 50.07 (±12.82) |
| >50 | 55 (59.1%) |
| Age at diagnosis of ovarian metastases, years (±SD) | | |
| ≤50 | 50.66 (±12.90) |
| >50 | 49 (52.7%) |
| Menopausal status at diagnosis of ovarian metastases | | |
| No | 55 (59.1%) |
| Yes | 38 (40.9%) |
| Primary tumor site | | |
| Right colon | 24 (25.8%) |
| Left colon | 43 (46.2%) |
| Rectum | 26 (28.0%) |
| Ovarian metastasis | | |
| Synchronous | 54 (58.1%) |
| Metachronous | 39 (41.9%) |
| Internal time, months (quartile) | | |
| | 12 (8–18.5) |
| Extent of metastatic disease | | |
| Ovary-only metastases | 37 (39.8%) |
| Combined with other metastases | 56 (60.2%) |
| Liver | 35 (62.5%) |
| Lung | 17 (30.4%) |
| Bone | 2 (3.6%) |
| Peritoneum | 23 (41.1%) |
| Surgery | | |
| No resection of ovarian metastases | 17 (18.3%) |
| Resection of ovarian metastases | 76 (81.7%) |
| Adjuvant chemotherapy | | |
| None | 7 (7.5%) |
| FOLFOX/FOLFIRI/CapeOx | 49 (52.7%) |
| FOLFOX/FOLFIRI/CapeOx+Bmab | 8 (8.6%) |
| FOLFOX/FOLFIRI+Cmab | 9 (9.7%) |
| 5-Fu/Cape | 6 (6.4%) |
| Unknown | 14 (15.1%) |
| OS, months | 26 |

Abbreviations: CRC-OM, colorectal cancer ovarian metastases; SD, standard deviation; OS, overall survival; FOLFOX, 5-FU + leucovorin + oxaliplatin; FOLFIRI, 5-FU + leucovorin + irinotecan; Cape, capcitabine; CapeOX, capcitabine + oxaliplatin; Bmab, bevacizumab; Cmab, cetuximab.
Resection of ovarian metastases was significantly associated with longer OS (HR (95% CI), 4.864 (2.598–9.110), p<0.001) for CRC-OM patients (Figure 3B) and for patients with metastases in one or more organs in addition to the ovary (HR (95% CI), 4.420 (1.566–12.48), p=0.005) (Figure 3C). Additionally, age <50 years at diagnosis of CRC and ovarian metastasis may indicate a worse OS (p=0.037, p=0.027). In addition, there was no significant correlation between prognosis and menopausal status, primary tumor site, synchronous or metachronous metastases, postoperative chemotherapy or adjuvant chemotherapy. Multivariate analysis showed that patients with ovarian metastases alone had a longer OS time (HR (95% CI), 3.633 (1.678–7.868), p=0.001). Moreover, longer OS (HR (95% CI), 3.508 (1.503–8.190), p=0.002) was significantly associated with ovarian metastasis resection (Table 2).
Factors Affecting CRC-OM Surgery

To explore the factors that affected the feasibility of metastasis resection, a comparison of the characteristics of patients with and without resection of ovarian metastases was carried out. We found that the combination of ovarian metastases with other metastases was the only associated factor (p<0.001). Other factors including age at diagnosis of CRC or ovarian metastases, menopausal status, primary tumor site, synchronous or metachronous ovarian metastases, and chemotherapy were not significantly related to conducting surgical treatments (Table 3). The results indicated that the assessment of the extent of metastases was important for determining surgical treatment.

Comparison Between Synchronous and Metachronous Ovarian Metastases

To explore the characteristics and prognosis of patients with synchronous or metachronous ovarian metastases, 54 patients with synchronous and 39 patients with metachronous metastases were enrolled in this study (n=93), among whom 42 synchronous and 34 metachronous metastasis patients underwent metastasis resection. The

Table 2 Univariate and Multivariate Analyses of OS in All Patients with CRC-OM

| Variables                                      | Univariate Analysis | Multivariate Analysis |
|-----------------------------------------------|---------------------|-----------------------|
|                                               | HR (95% CI)         | P value               |
|                                               |                     | HR (95% CI)           | P value               |
| Age at diagnosis of primary colorectal cancer, years (±SD) ≤50 | 1 (reference) 0.52 (0.28–0.96) | 0.037 | 1.07 (0.23–4.98) | 0.934 |
| >50                                           |                     |                       |                       |
| Age at diagnosis of ovarian metastases, years (±SD) ≤50 | 1 (reference) 0.51 (0.28–0.93) | 0.027 | 0.58 (0.13–2.50) | 0.461 |
| >50                                           |                     |                       |                       |
| Menopausal status at diagnosis of ovarian metastases No | 1 (reference) 0.62 (0.34–1.13) | 0.12 | NA | NA |
| Yes                                           |                     |                       |                       |
| Primary tumour site                           |                     |                       |                       |
| Right colon                                   | 1 (reference) 1.70 (0.78–3.74) | 0.174 | NA | NA |
| Left colon                                    | 2.22 (0.96–5.12)    |                       |                       |
| Rectum                                       |                     |                       |                       |
| Ovarian metastasis                           |                     |                       |                       |
| Synchronous                                   | 1 (reference) 0.89 (0.48–1.63) | 0.694 | NA | NA |
| Metachronous                                  |                     |                       |                       |
| Extent of metastatic disease                  |                     |                       |                       |
| Ovary-only metastases                         | 1 (reference) 4.86 (2.60–9.11) | <0.001 | 3.63 (1.68–7.87) | 0.001 |
| Combined with other metastases                |                     |                       |                       |
| Surgery                                       |                     |                       |                       |
| Resection of ovarian metastases               | 1 (reference) 5.33 (2.46–11.54) | <0.001 | 3.51 (1.50–8.19) | 0.002 |
| No resection of ovarian metastases            |                     |                       |                       |
| Adjuvant chemotherapy                         |                     |                       |                       |
| None                                          | 1 (reference) 0.65 (0.23–1.85) | 0.271 | NA | NA |
| FOLFOX/FOLFIRI/CapeOx                         | 1.33 (0.28–6.26)    |                       |                       |
| FOLFOX/FOLFIRI/CapeOx+Bmab                    | 0.34 (0.08–1.40)    |                       |                       |
| FOLFOX/FOLFIRI+Cmab                           | 0.33 (0.06–1.81)    |                       |                       |
| S-Fu/Cape                                     |                     |                       |                       |

Note: A p-value in bold type means a significant difference (p < 0.05).

Abbreviations: CRC-OM, colorectal cancer ovarian metastases; SD, standard deviation; OS, overall survival; HR, hazard ratio; CI, confidence interval; FOLFOX, 5-FU + leucovorin + oxaliplatin; FOLFIRI, 5-FU + leucovorin + irinotecan; Cape, capecitabine; CapeOX, capecitabine + oxaliplatin; Bmab, bevacizumab; Cmab, cetuximab.
Table 3 Comparison of the Characteristics of Patients with and without Resection of Ovarian Metastases

| Variables                              | No Resection of Ovarian Metastases | Resection of Ovarian Metastases | P value |
|----------------------------------------|------------------------------------|---------------------------------|---------|
| Age at diagnosis of colorectal cancer, years (±SD) ≤50 | 49.77 (±13.77) | 50.13 (±12.69) | 0.916   |
|                                        | 11 (64.7%)                             | 44 (57.9%)                         | 0.606   |
|                                        | 6 (35.3%)                              | 32 (42.1%)                          |         |
| Age at diagnosis of ovarian metastases, years (±SD) ≤50 | 50.18 (±13.70) | 50.76 (±12.81) | 0.867   |
|                                        | 11 (64.7%)                             | 38 (50.0%)                         | 0.272   |
|                                        | 6 (35.3%)                              | 38 (50.0%)                          |         |
| Menopausal status at diagnosis of ovarian metastases | No | 11 (64.7%) | 44 (57.9%) | 0.606   |
|                                        | Yes | 6 (35.3%) | 32 (42.1%) |         |
| Primary tumor site                     | Right colon | 3 (17.6%) | 21 (27.6%) | 0.625   |
|                                        | Left colon | 8 (47.1%) | 35 (46.1%) |         |
|                                        | Rectum | 6 (35.3%) | 20 (26.3%) |         |
| Ovarian metastasis                     | Synchronous metastases | 12 (70.6%) | 42 (55.3%) | 0.247   |
|                                        | Metachronous metastases | 5 (29.4%) | 34 (44.7%) |         |
| Extent of metastatic disease           | Ovary-only metastases | 0 (0.0%) | 37 (48.7%) | <0.001  |
|                                        | Combined with other metastases | 17 (100.0%) | 39 (51.3%) |         |
| Adjuvant chemotherapy                  | None | 1 (5.9%) | 6 (7.9%) | 0.673   |
|                                        | FOLFOX/FOLFIRI/CapeOx | 9 (52.9%) | 40 (52.6%) |         |
|                                        | FOLFOX/FOLFIRI/CapeOx+Bmab | 2 (11.8%) | 6 (7.9%) |         |
|                                        | FOLFOX/FOLFIRI+Cmab | 3 (17.6%) | 6 (7.9%) |         |
|                                        | 5-Fu/Cape | 0 (0.0%) | 6 (7.9%) |         |
|                                        | Unknown | 2 (11.8%) | 12 (15.8%) |         |

Note: A p-value in bold type means a significant difference (p < 0.05).

Abbreviations: SD, standard deviation; FOLFOX, 5-FU + leucovorin + oxaliplatin; FOLFIRI, 5-FU + leucovorin + irinotecan; Cape, capcitabine; CapeOX, capecitabine + oxaliplatin; Bmab, bevacizumab; Cmab, cetuximab.

The median interval between CRC surgery and detection of synchronous ovarian metastases was 12 months (range: 3–43 months). The majority (85.3%) developed ovarian metastases 2 years after CRC surgery. The clinicopathological information of the synchronous and metachronous ovarian metastasis groups was compared. Features including age under 50 years (p=0.020) and premenopausal status (p=0.030) were found to be characteristic of synchronous metastasis cases (Table 4). Survival analysis showed no significant difference in OS between synchronous and metachronous ovarian metastasis cases (HR 95% CI, 1.127 (0.614–2.09), p=0.689) (Figure 4A).

CRC Ovary-Only Metastasis Patients Could Achieve Similar Survival Outcomes to Those of Patients Without Metastases After Surgery

To further clarify the benefits of surgery for CRC-OM patients after resection of primary and ovarian metastasis sites, for the first time, 38 patients without metastases who underwent CRC surgery were selected for a 1:2 match with only synchronous ovarian metastasis patients. After matching, there was no significant difference in those factors between the two groups (p=0.1) (Table 5). Survival analysis showed no significant difference after surgery between patients with only ovarian metastases and patients without any metastases, regardless of whether
Table 4 Comparison of the Characteristics of Synchronous and Metachronous Ovarian Metastases Patients

| Variables                                | Synchronous Metastases | Metachronous Metastases | P value |
|------------------------------------------|------------------------|-------------------------|---------|
| Age at diagnosis of colorectal cancer, years (±SD) ≤50 | 49.09 (±13.39)          | 51.41 (±12.02)          | 0.393   |
|                                          | 34 (63.0%)              | 21 (53.8%)              | 0.377   |
|                                          | 20 (37.0%)              | 18 (36.2%)              |         |
| Age at diagnosis of ovarian metastases, years (±SD) ≤50 | 49.09 (±13.39)          | 52.82 (±12.03)          | 0.171   |
|                                          | 34 (63.0%)              | 15 (38.5%)              | 0.02    |
|                                          | 20 (37.0%)              | 24 (61.5%)              |         |
| Menopausal status at diagnosis of ovarian metastases |                        |                        | 0.03    |
| No                                       | 37 (68.5%)              | 21 (53.8%)              |         |
|                                          | 17 (31.5%)              | 18 (36.2%)              |         |
| Primary tumor site                       |                        |                        | 0.377   |
| Right colon                              | 14 (25.9%)              | 10 (25.6%)              |         |
| Left colon                               | 22 (40.8%)              | 21 (53.8%)              |         |
| Rectum                                   | 18 (33.3%)              | 8 (20.6%)               |         |
| Extent of metastatic disease             |                        |                        | 0.286   |
| Ovary-only metastases                    | 19 (35.2%)              | 18 (36.2%)              |         |
| Combined with other metastases           | 35 (64.8%)              | 21 (53.8%)              |         |
| Surgery                                  |                        |                        | 0.247   |
| No resection of ovarian metastases       | 12 (22.2%)              | 5 (12.8%)               |         |
| Resection of ovarian metastases          | 42 (77.8%)              | 34 (87.2%)              |         |
| Adjuvant chemotherapy                    |                        |                        | 0.149   |
| None                                     | 4 (7.4%)                | 3 (7.7%)                |         |
| FOLFOX/FOLFIRI/CapeOx                    | 30 (55.6%)              | 19 (48.7%)              |         |
| FOLFOX/FOLFIRI/CapeOx+Bmab               | 6 (11.1%)               | 2 (5.1%)                |         |
| FOLFOX/FOLFIRI+Cmab                      | 7 (13.0%)               | 2 (5.1%)                |         |
| 5-Fu/Cape                                | 1 (1.9%)                | 5 (12.8%)               |         |
| Unknown                                  | 6 (11.1%)               | 8 (20.6%)               |         |

Note: A p-value in bold type means a significant difference (p < 0.05).
Abbreviations: SD, standard deviation; FOLFOX, 5-FU + leucovorin + oxaliplatin; FOLFIRI, 5-FU + leucovorin + irinotecan; Cape, capecitabine; CapeOX, capecitabine + oxaliplatin, Bmab, bevacizumab; Cmab, cetuximab.

DFS (p=0.799, HR (95% CI), 1.154 (0.382–3.483)) or OS (p=0.848, HR (95% CI), 1.112 (0.376–3.283)) (Figure 5A and B) was analyzed.

In summary, the results indicated that after resection of primary and metastatic lesions, the DFS and OS of patients with only ovarian metastases were not different from those of patients without any metastases.

Discussion

CRC-OM is an important cause of death among female patients who are not sensitive to chemotherapy and have a poor prognosis. Six studies in the past 20 years showed that the median survival time of CMC-OM was 15–43.1 months.5,8–12 In this study, the median survival time of all patients was 29 months. CRC patients with only ovarian metastases had a better survival outcome, with a median OS of 49 months, while patients with other metastases had a worse prognosis, with a median OS of 20 months. Therefore, the combination with other metastases might be responsible for the poor prognosis of CRC-OM.

The median survival time of the patients with primary tumor and ovarian metastasis resection was 34 months. Multiple-factor analysis showed whether combined metastases in addition to ovary and ovary resection were vital factors affecting the prognosis of patients with CRC-OM. CRC-OM patients with other metastases who underwent removal of primary lesions and resection of ovarian metastases could also have an improved OS. All of the above findings suggest that surgical removal of the primary tumor and ovarian metastases can effectively improve the survival outcome. An increasing number of scholars have proposed that aggressive surgical treatment is an important therapeutic approach to ovarian metastases. Compared with simple systemic chemotherapy, it can significantly
improve the survival time.\textsuperscript{5,9,12,13} Most studies also agree that the extent of tumor metastasis is an important factor affecting the prognosis of patients.\textsuperscript{14-17} Metastasis beyond the pelvic cavity, especially peritoneal metastasis, often indicates a poor prognosis.\textsuperscript{11,18} The mean age at diagnosis of CRC was 50.07 years (range: 26–78, SD: 12.82), which was much younger than CRC female patients without ovarian metastases (n=4542, median age: 62, range: 19–92, p<0.001). In addition, we found that in CRC-OM patients, the proportion of premenopausal patients (59.1%) was higher than that of menopausal patients (40.9%). Mille et al\textsuperscript{8} found that 28% of premenopausal women with CRC may have ovarian metastases, while only 3.6% of menopausal women do. This may be related to the rich local blood supply of young women’s ovaries. Whether it is related to the level of female hormones needs further research. In our study, most of the patients with ovarian metastases received adjuvant chemotherapy after operation. We also compared chemotherapy and different chemotherapy schemes, but no significant differences were found, which may be related to ovarian metastases being insensitive to chemotherapy compared with other metastases. The result was consistent with previous reports. Sekine et al\textsuperscript{5} found that only 23.5% of CRC-OM patients were sensitive to palliative chemotherapy. Goere et al\textsuperscript{6} provided the evidence that more than 80% of CRC-OM patients could not escape disease progression after treatment with preoperative chemotherapy. In conclusion, systemic chemotherapy alone may provide very limited improvement on the prognosis of patients.\textsuperscript{6} We also compared the characteristics of patients with and without resection of ovarian metastases and determined whether other metastases in addition to those of the ovary were important for the surgeon’s evaluation of the feasibility of surgery.

Several single-center studies of more than 100 cases showed that the incidence rate of synchronous OM was 0–9% and that the incidence rate of metachronous OM was 0.9–7%.\textsuperscript{14,19,20} We also compared the survival times of patients with synchronous ovarian metastases and to those of patients with metachronous ovarian metastases; there were no statistically significant differences. Some studies approved that synchronous or metachronous ovarian metastases were not the vital factor for the prognosis of CRC-OM patients.\textsuperscript{14} But some other studies thought the survival of synchronous metastases was much better.\textsuperscript{21} We also found patients with synchronous ovarian metastases tended to be younger than 50 years and premenopausal, so young women with CRC need to be more alert to the possibility of ovarian metastases. Metachronous ovarian metastases usually occurred within 2 years after the CRC operation, which suggested that female patients should be aware of the possibility of metachronous ovarian metastases within 2 years after the CRC operation to facilitate early detection and treatment for a better prognosis. But Kim et al\textsuperscript{14} suggested that (82.8%) patients had metachronous metastases within 3 years. Larger samples and prospective clinical researches are needed to further identify.

To further clarify the benefits of surgical resection of metastases, we matched and then analyzed the data of patients with only synchronous ovarian metastases and those with no metastases. Although the prognosis of patients with ovarian metastases is poor, we first found
Table 5 A:1:2 Matched Analysis Using Without Metastasis Cases as Control from 3872 Colorectal Cancer Cases During 2008 to 2018

| Covariates                              | Matched Cohort | Ovarian Metastases | Without Ovarian Metastases | P value |
|-----------------------------------------|----------------|--------------------|---------------------------|---------|
| Age, years (±SD)                        |                | 53.68±15.57        | 49.32±15.06               | 0.312   |
| Preoperative radiotherapy or chemotherapy |                |                    |                           |         |
| No                                      |                | 17 (89.5%)         | 36 (94.7%)                | 0.463   |
| Yes                                     |                | 2 (10.5%)          | 2 (5.3%)                  |         |
| Primary tumor site                      |                |                    |                           |         |
| Right colon                             |                | 6 (31.6%)          | 11 (28.9%)                | 0.708   |
| Left colon                              |                | 5 (26.3%)          | 7 (18.4%)                 |         |
| Rectum                                  |                | 8 (42.1%)          | 20 (52.6%)                |         |
| Primary tumor size, cm (±SD)            |                | 5.00 (4.00–7.00)   | 4.50 (3.38–6.00)          | 0.175   |
| Operation method                        |                |                    |                           |         |
| Laparotomy                              |                | 13 (68.4%)         | 18 (47.4%)                | 0.132   |
| Minimally invasive                      |                | 6 (31.6%)          | 20 (52.6%)                |         |
| T-stage of primary tumor                |                |                    |                           |         |
| 2                                       |                | 0 (0.0%)           | 0 (0.0%)                  | 0.849   |
| 3                                       |                | 8 (42.1%)          | 15 (39.5%)                |         |
| 4                                       |                | 11 (57.9%)         | 23 (60.5%)                |         |
| N-stage of primary tumor                |                |                    |                           |         |
| 0                                       |                | 3 (15.8%)          | 7 (18.4%)                 | 0.958   |
| 1                                       |                | 5 (26.3%)          | 9 (23.7%)                 |         |
| 2                                       |                | 11 (57.9%)         | 22 (57.9%)                |         |
| Primary tumor gross type                |                |                    |                           |         |
| Protruding                              |                | 6 (31.6%)          | 14 (36.8%)                | 0.924   |
| Ulcerative                              |                | 12 (63.1%)         | 22 (57.9%)                |         |
| Constrictive                            |                | 1 (5.3%)           | 2 (5.3%)                  |         |
| Primary tumor histology                 |                |                    |                           |         |
| Adenocarcinoma                          |                | 14 (73.7%)         | 30 (78.9%)                | 0.885   |
| Mucinous                                |                | 4 (21.1%)          | 6 (15.8%)                 |         |
| Signet ring cell type                   |                | 1 (5.2%)           | 2 (5.3%)                  |         |
| Primary tumor differentiation           |                |                    |                           |         |
| Moderately differentiated               |                | 7 (36.8%)          | 10 (26.3%)                | 0.413   |
| Poorly differentiated                   |                | 12 (63.2%)         | 28 (73.7%)                |         |

Abbreviations: SD, standard deviation; FOLFOX, 5-FU + leucovorin + oxaliplatin; FOLFIRI, 5-FU + leucovorin + irinotecan; Cape, capecitabine; CapeOX, capecitabine + oxaliplatin, Bmab, bevacizumab; Cmab, cetuximab.
investigations were conducted according to the principles expressed in the Declaration of Helsinki. Each subject provided their written informed consent.

Acknowledgments
Yuqiu Xu would like to thank Dr. Feng, Dr Xu and Dr. He for their careful guidance in this thesis.

Author Contributions
All authors made substantial contributions to conception and design, acquisition and analysis of data; took part in drafting and revising the article; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
2. Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 2019;41(1):19–28. doi:10.3760/cma.j.issn.0253-3766.2019.01.005
3. Wright JD, Powell MA, Mutch DG, et al. Synchronous ovarian metastases at the time of laparotomy for colon cancer. Gynecol Oncol. 2004;92(3):851–855. doi:10.1016/j.ygyno.2003.12.017
4. Grafner OL, Alm OA, O'scarson EA. Prophylactic oophorectomy in colorectal carcinoma. Obstet Gynecol Surv. 1983;146(23):226–228.
5. Sekine K, Hamaguchi T, Shoji H, et al. Retrospective analyses of systemic chemotherapy and cytoreductive surgery for patients with ovarian metastases from colorectal cancer: a single-center experience. Oncology. 2018;95(4):220–228. doi:10.1159/000489665
6. Goere D, Daveau C, Elias D, et al. The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. Eur J Surg Oncol. 2008;34(12):1335–1339. doi:10.1016/j.ejso.2008.03.010
7. Ursem C, Zhou M, Paciorek A, et al. Clinicopathologic characteristics and impact of oophorectomy for ovarian metastases from colorectal cancer. Oncologist. 2020;25(7):564–571. doi:10.1634/theoncologist.2019-0282
8. Mille BE, Pittman B, Wan JY, Fleming M. Colon cancer with metastasis to the ovaries at time of initial diagnosis. Gynecol Oncol. 1997;66(3):368–371. doi:10.1016/ygyno.1997.4811
9. McCormick CC, Giuntoli RL, 2nd, Gardner GJ, et al. The role of cytoreductive surgery for colon cancer metastatic to the ovary. Gynecol Oncol. 2007;105(3):791–795. doi:10.1016/j.gyno.2007.02.025
10. Chung TS, Chang HJ, Jung KH, et al. Role of surgery in the treatment of ovarian metastases from colorectal cancer. J Surg Oncol. 2009;100(7):570–574. doi:10.1002/jso.21382
11. Fujiiwara A, Noura S, Ohue M, et al. Significance of the resection of ovarian metastasis from colorectal cancers. J Surg Oncol. 2010;102(6):582–587. doi:10.1002/jso.21675

Conclusion
CRC-OM patients could achieve longer survival times after primary and metastatic lesion surgery. There was no significant difference in OS after surgery between patients with only ovarian metastases and patients without metastases. There was no significant difference in the prognosis of patients with synchronous and those with metachronous ovarian metastases. Hence, our study suggests aggressive surgical treatment for patients with CRC-OM to help achieve a better prognosis.

Ethical Approval and Informed Consent
The study was approved by the Ethics Committee of Zhongshan Hospital, Fudan University. All clinical
12. Ganesh K, Shah RH, Vakiani E, et al. Clinical and genetic determinants of ovarian metastases from colorectal cancer. Cancer. 2017;123(7):1134–1143. doi:10.1002/cncr.30424
13. Erroi F, Scarpa M, Angriman I, et al. Ovarian metastasis from colorectal cancer: prognostic value of radical oophorectomy. J Surg Oncol. 2007;96(2):113–117. doi:10.1002/jso.20803
14. Kim DD, Park JJ, Kim HC, Yu CS, Kim JC. Ovarian metastases from colorectal cancer: a clinicopathological analysis of 103 patients. Colorectal Dis. 2009;11(1):32–38. doi:10.1111/j.1463-1318.2008.01543.x
15. Rayson D, Bouttell E, Whiston F, Stitt L. Outcome after ovarian or adnexal metastectomy in metastatic colorectal carcinoma. J Surg Oncol. 2000;75:186–192. doi:10.1002/1096-9098(200011)75:3<186::AID-JSO6>3.0.CO;2-S
16. Lee SJ, Lee J, Lim HY, et al. Survival benefit from ovarian metastasectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis. Cancer Chemother Pharmacol. 2010;66(2):229–235. doi:10.1007/s00280-009-1150-2
17. Xu KY, Gao H, Lian ZJ, Ding L, Li M, Gu J. Clinical analysis of Krukenberg tumours in patients with colorectal cancer - a review of 57 cases. World J Surg Oncol. 2017;15(1):25. doi:10.1186/s12957-016-1087-y
18. Tan KL, Tan WS, Lim JF, Eu KW. Krukenberg tumors of colorectal origin: a dismal outcome–experience of a tertiary center. Int J Colorectal Dis. 2010;25(2):233–238. doi:10.1007/s00384-009-0796-x
19. Hanna NN, Cohen AM. Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer. 2004;3(4):215–222. doi:10.3816/CCC.2004.n.002
20. Alberto C, Snehzi R, Piniella F, et al. Management of non-hepatic metastatic disease in colorectal cancer. Surg Diag Treat. 2014;191. doi:10.5772/57487
21. Huang PP, Weber TK, Mendoza C, Rodriguez-Bigas MA, Petrelli NJ. Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol. 1998;5(8):695–698. doi:10.1007/bf02303479